Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biomea Fusion, Inc. - Common Stock (NQ:BMEA)

1.681 -0.049 (-2.85%)
Streaming Delayed Price Updated: 10:19 AM EDT, Aug 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biomea Fusion, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Gold Falls Sharply; Geron Shares Spike Higher ↗
 
Via Benzinga
News headline image
Recap: Biomea Fusion Q4 Earnings ↗
 
Via Benzinga
News headline image
Why Biomea Fusion (BMEA) Stock Is Down 60% ↗
Biomea Fusion shares are trading lower by 62.7% during Friday's session. The company received notice from the FDA that Its trials of BMF-219 have been placed on clinical hold. 
Via Benzinga
News headline image
US Stocks Lower; Nonfarm Payrolls Increase More Than Expected ↗
 
Via Benzinga
News headline image
Biomea Fusion Crashes 65% After FDA Puts Diabetes Treatment Studies On Hold ↗
The FDA cited concerns of liver toxicity, but the company says its drug has been generally well-tolerated. 
Via Investor's Business Daily
News headline image
Why Is Virax Biolabs (VRAX) Stock Down 15% Today? ↗
Virax Biolabs stock is down on Friday as shares of VRAX come off of a massive rally yesterday that didn't come with any news. 
Via InvestorPlace
News headline image
Vail Resorts Posts Downbeat Q3 Results, Joins Concrete Pumping, DocuSign And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Is Biomea Fusion (BMEA) Stock Down 63% Today? ↗
Biomea Fusion stock is falling on Friday after investors learned of the FDA placing a clinical hold on its Phase I/II clinical trials. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
Pre-market stock movers are worth checking out on Friday as we dig into all of the biggest news affecting shares this morning! 
Via InvestorPlace
News headline image
This Pharma Stock Dropped 60% Premarket As FDA Halted Diabetes Drug Trials ↗
Elevated liver enzyme levels were noted, although most adverse events were mild to moderate, with no severe reactions reported. 
Via Benzinga
News headline image
Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze ↗
Though short squeezes are never guaranteed, these three potential short squeeze stocks could provide generous returns if bought right. 
Via InvestorPlace
News headline image
Why Braze Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Biomea Fusion, Inc. and Encourages Investors with Losses to Contact the Firm
From Schall Law
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Short Squeeze Specialists: 3 Stocks With the Expertise to Defy Bearish Expectations ↗
Sometimes the bears can push their luck too much, leading to a reverse response. That’s the incentive behind these short squeeze stocks. 
Via InvestorPlace
News headline image
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells 
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
BMEA Stock Earnings: Biomea Fusion Misses EPS for Q1 2024 ↗
BMEA stock results show that Biomea Fusion missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
BMEA Stock Earnings: Biomea Fusion Misses EPS for Q4 2023 ↗
BMEA stock results show that Biomea Fusion missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode ↗
Bullish speculators could have their opportunity to blow up the bears with these short-squeeze stocks to buy. 
Via InvestorPlace
News headline image
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
From Biomea Fusion, Inc.
Via GlobeNewswire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.